Company intelligence / Profile preview

Orgamol

Evionnaz, Valais, Switzerland

Ownership: Private
Development stage: Other

Overview

Orgamol, historically an independent Swiss-based custom manufacturer of pharmaceutical fine chemicals and APIs, was acquired by BASF in 2005 and is now a central part of BASF’s pharmaceutical solutions division, manufacturing active ingredients, excipients, and intermediates to cGMP standards for global pharma clients[1][2][3][4][5].

Modalities: Small molecule
Industry: Contract Manufacturing Organization

Partnerships

Multiple pharmaceutical companies as contract manufacturing clients

Beyond the preview

Go deeper on Orgamol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orgamol.

Explore the full profile